F. Barry Bays - Jan 11, 2023 Form 4 Insider Report for TREACE MEDICAL CONCEPTS, INC. (TMCI)

Role
Director
Signature
/s/ Lisa Taylor as Attorney-in-fact for F. Barry Bays
Stock symbol
TMCI
Transactions as of
Jan 11, 2023
Transactions value $
-$1,398,505
Form type
4
Date filed
1/13/2023, 08:00 PM
Previous filing
Dec 21, 2022
Next filing
Jan 26, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TMCI Common Stock Sale -$236K -9.72K -0.67% $24.32 1.44M Jan 11, 2023 Direct F1, F2, F3
transaction TMCI Common Stock Sale -$596K -23.7K -1.65% $25.13 1.41M Jan 12, 2023 Direct F1, F3, F4
transaction TMCI Common Stock Sale -$567K -21.8K -1.55% $25.94 1.39M Jan 12, 2023 Direct F1, F3, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $24.0500 to $24.755 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 Due to an inadvertent error, the value in Table 1, Box 5 of the Form 4 filed on September 29, 2022 was incorrectly reported. This value corrects the aforementioned error.
F4 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $24.5500 to $25.5400 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.5500 to $25.9900 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.